Voltar
Revisão Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN’S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN’S DISEASE AND COLITIS (GEDIIB)

2023; Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE); Linguagem: Inglês

10.1590/s0004-2803.2022005s1-02

ISSN

1678-4219

Autores

Marcello Imbrizi, Júlio Pinheiro Baima, Matheus Freitas Cardoso de Azevedo, Adriana Ribas Andrade, Natália Sousa Freitas Queiroz, Júlio Maria Fonseca Chebli, Liliane Andrade CHEBLI, Marjorie Argollo, Lígia Yukie Sassaki, Rogério Serafim Parra, Abel Botelho Quaresma, Andréa Vieira, Adérson Omar Mourão Cintra Damião, Antônio Carlos Moraes, Cristina Flores, Cyrla Zaltman, Eduardo García Vilela, Eloá Marussi Morsoletto, Francisco de Assis Gonçalves Filho, Francisco Guilherme Cancela e Penna, Genoile Oliveira Santana, Gilmara Pandolfo Zabot, José Miguel Luz Parente, Márcia Henriques de Magalhães Costa, Marco Zerôncio, Marta Brenner Machado, Ornella Sari Cassol, Paulo Gustavo Kotze, Renata de Sá Brito Fróes, Sender Jankiel Miszputen, Orlando Ambrogini, Rogério Saad-Hossne, Cláudio Saddy Rodrigues Coy,

Tópico(s)

Pregnancy and Medication Impact

Resumo

Background: Inflammatory bowel disease (IBD) is an immune-mediated disorder that includes Crohn's disease (CD) and ulcerative colitis. CD is characterized by a transmural intestinal involvement from the mouth to the anus with recurrent and remitting symptoms that can lead to progressive bowel damage and disability over time. Objective: To guide the safest and effective medical treatments of adults with CD. Methods: This consensus was developed by stakeholders representing Brazilian gastroenterologists and colorectal surgeons (Brazilian Organization for Crohn's disease and Colitis (GEDIIB)). A systematic review of the most recent evidence was conducted to support the recommendations/statements. All included recommendations and statements were endorsed in a modified Delphi panel by the stakeholders and experts in IBD with an agreement of at least 80% or greater consensus rate. Results and conclusion: The medical recommendations (pharmacological and non-pharmacological interventions) were mapped according to the stage of treatment and severity of the disease in three domains: management and treatment (drug and surgical interventions), criteria for evaluating the effectiveness of medical treatment, and follow-up/patient monitoring after initial treatment. The consensus is targeted towards general practitioners, gastroenterologists, and surgeons interested in treating and managing adults with CD and supports the decision-making of health insurance companies, regulatory agencies, and health institutional leaders or administrators.

Referência(s)